KFDA approved compassionate use of Iressa.

Published: 2001-12-11 07:00:00

Updated: 2001-12-11 07:00:00

The KFDA approved Astra-Zeneca's Iressa, a cancer drug, for a compassionate use in treatment of advanced non cellular lung cancer. Iressa is a new anti-tumor drug still under phase III clinical studies in the United States and expected to be released in the commercial market around the first half...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK